The CYP2D6 metaboliser status of patients prescribed risperidone for the treatment of psychosis

New Zealand Medical Journal

Volumn 122, Issue 1296, 2009, Pages 29-34

  Dunbar, Lucy ^a   Miles, Wayne ^b   Wheeler, Amanda ^a   Sheridan, Janie ^c   Pulford, Justin ^a   Butler, Rachael ^a  

^a WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; RISPERIDONE;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; ETHNIC DIFFERENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; PSYCHOSIS; SEX DIFFERENCE; SOCIAL STATUS; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; OCEANIC ANCESTRY GROUP; PHENOTYPE; POLYMORPHISM, GENETIC; PSYCHOTIC DISORDERS; RISPERIDONE;

EID: 67649962141     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Collins FS, McKusick VA. Implications of the Human Genome Project for Medical Science. JAMA. 2001;285(5):540-544.
2. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Nauyn-Schmiedeberg's Arch Pharmacol. 2004;369:23-3.
3. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics Journal. 2005;5(1):6-13.
4. de Leon J, Susce MT, Pan RM. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. Journal of Clinical Psychiatry. 2005;66:15-27.
5. Kaiser R, Sezer O, Papies A, et al. Patient-Tailored Antiemetic Treatment With 5-Hydroxytryptamine Type 3 Receptor Antagonists According to Cytochrome P-450 2D6 Genotypes. J Clin Oncol. 2002;20(12):2805-2811.
6. Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist. 2006;11(2):126-35.
7. Lea RA, Roberts RL, Green MR, et al. Allele frequency differences of cytochrome P450 polymorphisms in a sample of New Zealand Maori. New Zealand Medical Journal. 2008;121(1272):33-7.
8. Roberts RL, Begg EJ, Joyce PR, Kennedy, MA. How the pharmacogenetics of cytochrome P450 enzymes may affect prescribing. New Zealand Medical Journal. 2002;115(1150):137-40.
9. Mulder H, Wilmink FW, Beumer TL, et al. The association between cytochrome P450 2D6 genotype and prescription patterns of antipsychotic and antidepressant drugs in hospitalized psychiatric patients: a retrospective follow-up study. Journal of Clinical Psychopharmacology. 2005;25(2):188-91.
10. Plesnicar BK, Zalar B, Breskvar K, Dolzan V. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. Journal of Psychopharmacology. 2006;20(6):829-33.
11. New Zealand Health Information Service. Mental Health: Service use in New Zealand 2004. Ministry of Health: Wellington; 2007.
12. Statistics New Zealand. 2006 Census of Population and Dwellings. 2006.
13. Cai WM, Nikoloff DM, Pan RM, et al. CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing. Pharmacogenomics Journal. 2006;6(5):343-50.
14. Ingelman-Sundberg, M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2004;5(1):6-13.